Effect of ticagrelor and clopidogrel on serum inflammatory factor level in antiplatelet therapy for acute myocardial infarction patients after percutaneous coronary intervention

摘要

Objective: To compare the effect of ticagrelor and clopidogrel on serum inflammatory factor level in antiplatelet therapy for acute myocardial infarction (AMI) patients after percutaneous coronary intervention (PCI). Methods: 113 cases of AMI underwent PCI in our hospital from March 2016 to February 2018 were selected and divided into two groups. The experimental group (n=58) received the ticagrelor, while the control group (n=55) received the clopidogrel. Then the platelet aggregation, serum inflammatory factors, liver and kidney function, and cardiovascular and cerebrovascular events at the post 6-mon follow-up were compared between groups. Results: The platelet aggregation rate had no difference between the two groups before PCI (P>0.05), which were higher in the control group than in the experimental group at the post-PCI 24 h and 7 d (P0.05), which were higher in the control group than in the experimental group at the post-PCI 24 h and 7 d (P0.05). The serum creatinine (Scr) levels had no difference between the two groups before PCI (P>0.05), which were lower in the control group than in the experimental group at the post-PCI 24 h and 7 d (P<0.05). The incidence rate of the cardiovascular and cerebrovascular events at the post 6-months follow-up of the control group was higher than that of the experimental group (14.55% (8/55) vs 5.17% (3/58), P<0.05)Conclusion: Compared with the clopidogrel treatment, the application of ticagrelor has a better effect in antiplatelet therapy for AMI patients underwent PCI, which can effectively control serum inflammatory factor levels, stabilize liver function, reduce the occurrence of cardiovascular and cerebrovascular events, and improve the prognosis.